Welcome to our dedicated page for Genprex SEC filings (Ticker: GNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genprex, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage gene therapy company with common stock traded on The Nasdaq Capital Market under GNPX. The company’s 8-K reports record material-event disclosures on Reqorsa patent grants and patent-application actions, research agreements, investor presentations, preclinical and clinical data presentations, diabetes gene therapy updates, and Nasdaq listing-compliance matters.
Proxy materials provide governance and compensation disclosures, including director and executive compensation tables, pay-versus-performance information and annual meeting matters. The filing record also ties Genprex’s capital-market status to its common stock listing, minimum stockholders’ equity compliance, and Regulation FD treatment for furnished presentation materials and press-release exhibits.
Genprex, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 18, 2026. Investors will elect two Class III directors, hold an advisory vote on 2025 executive pay, and ratify WithumSmith+Brown, PC as independent auditor for 2026.
Stockholders will also vote on an amended and restated 2018 Equity Incentive Plan and a reverse stock split of common stock at a ratio between 1-for-5 and 1-for-50, which the board could implement any time before December 31, 2027. An adjournment proposal would allow the meeting to be postponed to solicit more proxies if needed. Stockholders of record on April 24, 2026, when 10,417,400 shares were outstanding and entitled to vote, may participate virtually via proxydocs.com/GNPX.
Genprex, Inc. reported that its research collaborators will present positive preclinical data on its diabetes gene therapy candidate GPX-002 (Pdx1/MafA gene therapy) at the 2026 American Society of Gene and Cell Therapy Annual Meeting in Boston.
In Type 2 diabetic mouse models induced by a high fat diet, intrapancreatic delivery of an AAV-8 vector encoding Pdx1 and MafA reversed hyperglycemia and restored glucose-stimulated insulin secretion to levels similar to mice on a regular diet. Electron microscopy and transcriptomic analyses showed more mature insulin granules and a shift of β-cells toward a mature state after treatment. The company highlighted that direct pancreatic delivery via endoscopic retrograde cholangiopancreatography could make this approach technically translatable to humans, while emphasizing usual forward-looking statement cautions and development risks.
Genprex, Inc. filed a report describing a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that may predict patient response to its Reqorsa Gene Therapy for non-small cell and small cell lung cancer.
The company also highlights progress in its Acclaim-1 and Acclaim-3 Phase 1/2 trials combining Reqorsa with Tagrisso and Tecentriq. Early Phase 1 data showed no dose limiting toxicities and signals of efficacy, including prolonged progression free survival and partial remissions in individual patients who continue on treatment.
Genprex, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 18, 2026, where stockholders will vote on director elections, ratification of WithumSmith+Brown, PC as auditor, an advisory vote on executive compensation, approval of an amended 2018 Equity Incentive Plan, and a proposed reverse stock split at a ratio between 1:5 and 1:50 (to be implemented at the Board’s discretion any time prior to December 31, 2027).
The record date for voting is April 24, 2026. The proxy materials, including the Company’s 2025 Annual Report on Form 10-K, will be mailed beginning on or about April (date omitted). The Board recommends voting FOR the named director nominees and the listed proposals.
Genprex, Inc. director Brent M. Longnecker reported small open-market sales of Genprex common stock, primarily for tax purposes. On April 14, 2026, he sold 8 shares of common stock at $1.23 per share from his direct holdings and 10 shares at $1.23 per share through indirect ownership by Longnecker Associates Ltd. Following these transactions, he directly holds 9,157 shares of Genprex common stock, with no remaining indirect shares reported in this filing.
Genprex, Inc. is a clinical-stage gene therapy company developing REQORSA for lung cancer and GPX-002 for Type 1 and Type 2 diabetes. REQORSA, delivered with the non-viral ONCOPREX system, is in Phase 2a Acclaim-1 for EGFR-mutant NSCLC and Phase 2 Acclaim-3 for extensive-stage small cell lung cancer, both with FDA Fast Track status and Orphan Drug Designation in SCLC.
The company is advancing preclinical GPX-002 diabetes programs after an FDA meeting in February 2026 on IND-enabling studies. Genprex strengthened liquidity via an at-the-market program, raising about $10.8 million in 2025 and $13.3 million through early 2026, executed two reverse stock splits to support Nasdaq listing, and regained compliance with Nasdaq equity and bid price rules. As of March 27, 2026, it had 9,044,856 common shares outstanding and a non-affiliate equity market value of about $7.5 million as of June 30, 2025.
Genprex, Inc. reported that its research collaborators will present three posters at the 2026 AACR Annual Meeting featuring new preclinical data on its lead candidate, REQORSA (quaratusugene ozeplasmid, “Quar Oze”), for non-small cell lung cancer.
The first study identifies TROP2 and PTEN expression patterns as potential biomarkers of primary resistance to TUSC2 gene therapy across NSCLC cell lines, organoids and xenograft models, helping explain which tumors may not respond.
The second study shows Quar Oze-driven TUSC2 overexpression induces strong tumor cell death in ALK-positive NSCLC models and enhances the effect of the ALK inhibitor alectinib, including in alectinib-resistant tumors, with combination treatment achieving the greatest tumor shrinkage and survival benefits in mice.
The third study demonstrates that restoring TUSC2 via Quar Oze boosts natural killer (NK) cell cytotoxicity, improves antitumor immune responses and, in many cases, leads to complete tumor regression in mouse models, supporting TUSC2 as both a tumor suppressor and immunomodulatory target.
Genprex, Inc.’s Chief Medical Officer, Mark Stanley Berger, reported a tax-related share withholding. On February 27, 2026, 7,168 shares of common stock were withheld to cover tax obligations tied to the vesting of Restricted Stock Units granted under Genprex’s 2018 Equity Incentive Plan. After this tax-withholding disposition, he directly owned 21,692 shares of Genprex common stock.
Genprex, Inc. director and executive officer Ryan M. Confer reported a Form 4 transaction showing a tax-withholding disposition of 9,330 shares of common stock at $2.00 per share. According to the disclosure, these shares were withheld on February 27, 2026 to satisfy tax withholding obligations tied to vesting restricted stock units granted under the company’s 2018 Equity Incentive Plan. After this withholding, Confer directly holds 36,331 shares of Genprex common stock.